Discovery of novel therapeutics through
the targetting of key enzymes in the kynurenine pathway
Leverage Experience in Drug Discovery & Development
Dedicated Translational Medicine Network
Initial KyNexis programs aimed at regulating Kynurenic acid levels in the brain to improve cognition
Robert SCHWARCZ, Ph.D.
Professor of Psychiatry, Pharmacology and Pediatrics, U. of Maryland School od Medicine, Baltimore, USA and Professor of Pharmacology, Karolinska Institutet,Stockholm,Sweden
Christer KÖHLER, Ph.D.
Chairman of the Board
Former VP and Head of CNS & Pain R&D, AstraZeneca and Global Head, CNS Discovery, Hoffman La-Roche
Chief of Legal and BD
Former Deputy General Counsel, Global R&D, AstraZeneca
Johan LUND, M.D., Ph.D.
Former VP and Global Head of Immunology & Inflammation R&D in Celgene, Pfizer and CNS VP, AstraZeneca
Translational Medicine Network
Dr. Carol TAMMINGA, M.D./Ph.D.
Chair, KyNexis Clinical Advisory Board
Chair in Brain Science and Chief of the Translational Neuroscience Division in Schizophrenia, UT Southwestern Medical Center in Dallas, Lou and Ellen McGinley Distinguished Chair in Psychiatric Research
Dr. Tamminga leads the B-SNIP (Bipolar and Schizophrenia Network for Intermediate Phenotypes) Consortium with 6 collaborating sites in the US which has Has established biologically distinct groups of psychosis patients based on factors such as brain waves, cognitive ability, and damage to brain tissue
We are KyNexis
We discover and develop targeted therapies that make a difference for patients
Office:Riddargatan 16, SE-11451 Stockholm, Sweden